Go to home

BioDay

BioDay Registry...

Description

The BioDay registry is a disease or condition registry for atopic dermatitis (AD)/prurigo nodularis (PN). All patients treated with advanced systemic therapy (biologics and JAK inhibitors [JAKi]) for AD are eligible for inclusion in the prospective, ...

General Design

Type
Registry
Data collection type
Prospective
Design
Longitudinal
Design description
Multicenter prospective observational atopic dermatitis registry
Start/End data collection
2017 (ongoing)
PID
https://doi.org/10.71739/feb4-qv18

Population

Countries
Netherlands (the)
Regions
Limburg, Zeeland, Zuid-Holland, Noord-Holland, Noord-Brabant, Flevoland, Utrecht, Gelderland, Overijssel, Friesland, Groningen
Number of participants
2295
Population age groups
All ages
Main medical condition
  • XII Diseases of the skin and subcutaneous tissue
Inclusion criteria
  • Defined population inclusion criterion
  • Use of medication inclusion criterion
Other inclusion criteria
Able and willing to sign informed consent form

Organisations

Lead organisations
Additional organisations

Contributors

  • prof. dr.  Marjolein de Bruin-WellerUniversity Medical Center Utrecht

    Principal Investigator

  • dr.  Marlies de GraafUniversity Medical Center Utrecht

    Primary contact

  • dr.  Inge HaeckUniversity Medical Center Utrecht

    Primary contact

  • dr.  Marie-Louise SchuttelaarUniversity Medical Center Groningen

    Primary contact

Available Data & Samples

Data categories

  • Biological samples
  • Survey data
  • Imaging data
  • Medical records
  • Physiological/Biochemical measurements
  • Other

Areas of information

  • Socio-demographic and economic characteristics
  • Lifestyle and behaviours
  • Birth, pregnancy and reproductive health history
  • Perception of health, quality of life, development and functional limitations
  • Symptoms and signs
  • Medication and supplements
  • Non-pharmacological interventions
  • Health and community care services utilization
  • Death
  • Physical measures and assessments
  • Laboratory measures
  • Cognition, personality and psychological measures and assessments

Subpopulations

List of subpopulations for this resource...

No results for current selection

Collection events

List of collection events defined for this resource...

No results for current selection

Networks

Part of networks...

  • Health data space Utrecht

    Welkom bij Health Data Space Utrecht, het portaal dat de regio Utrecht verbindt door onderzoekers en professionals samen te brengen om kennis en data te delen....

Publications

Association of Serum Dupilumab Levels at 16Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis
Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab
Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation
Drug Survival of Dupilumab,Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis Long-term Results From the Daily Practice BioDay Registry
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry
Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis
Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis
Early qualitative and quantitative amplitude-integrated electroencephalogram and raw electroencephalogram for predicting long-term neurodevelopmental outcomes in extremely preterm infants in the Netherlands: a 10-year cohort study
Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval
Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment
Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis
Limited excretion of dupilumab into breastmilk: A case report
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies
Non-Infectious Uveitis Secondary to Dupilumab Treatment in Atopic Dermatitis Patients Shows a Pro- Inflammatory Molecular Profile
Ocular surface disease in pediatric patients with moderate-to- severe atopic dermatitis
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry
Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients

Access conditions

Possible approval after data access request...

Data access conditions
  • health or medical or biomedical research
  • disease specific research
Data use conditions
  • not for profit, non commercial use only
  • collaboration required
  • user specific restriction
  • project specific restriction
Data access fee
false
Release type
Periodically
Release description
Quarterly data-locks are in place.
Prelinked
false

Funding & Acknowledgements

Funding
The BioDay Registry is sponsored by pharmaceutical companies of the biologicals and JAKi for AD (Sanofi Genzyme/Regeneron, Leo Pharma, Pfizer and Eli Lilly). These commercial sponsors do not have any influence on the collection and analyses of the data in the register.

Created with MOLGENIS